



**ANNUAL MEETING  
OF SHAREHOLDERS**

**TO BE HELD ON WEDNESDAY, OCTOBER 8, 2014**

**NOTICE OF MEETING  
AND MANAGEMENT INFORMATION CIRCULAR**

*THIS NOTICE OF MEETING AND MANAGEMENT INFORMATION CIRCULAR IS FURNISHED IN CONNECTION WITH THE SOLICITATION BY THE MANAGEMENT OF ZENITH EPIGENETICS CORP. OF PROXIES TO BE VOTED AT THE ANNUAL MEETING OF SHAREHOLDERS OF ZENITH EPIGENETICS CORP. TO BE HELD ON WEDNESDAY, OCTOBER 8, 2014.*

**TO BE HELD AT:  
Calgary TELUS Convention Centre  
The Glen Room 206  
120 – 9<sup>th</sup> Avenue SE  
Calgary, Alberta**

**At 10:30 a.m. (Calgary Time)**

Dated: August 25, 2014



**ZENITH EPIGENETICS CORP.**

**NOTICE OF ANNUAL MEETING TO BE HELD ON OCTOBER 8, 2014**

To: The holders of common shares (the "Common Shares"):

TAKE NOTICE that an Annual Meeting (the "**Meeting**") of the shareholders of Zenith Epigenetics Corp. (the "**Corporation**") will be held on Wednesday, October 8, 2014 at 10:30 a.m. (Calgary time), at the Calgary TELUS Convention Centre, The Glen Room 206, 120 – 9<sup>th</sup> Avenue SE, Calgary, Alberta for the following purposes:

1. to receive the audited financial statements of the Corporation for the year ended April 30, 2014 and the report of the auditors thereon;
2. to set the number of directors to be elected at the Meeting at six (6);
3. to elect directors for the ensuing year as described in the Management Information Circular accompanying this Notice;
4. to appoint auditors for the ensuing year and to authorize the directors to fix the remuneration to be paid to the auditors; and
5. to transact such other business that may properly come before the Meeting or adjournments thereof.

The board of directors has fixed the close of business on August 25, 2014 as the record date for determining holders of Common Shares who are entitled to notice of and to attend and vote at the Meeting.

Holders of Common Shares who are unable to be present at the Meeting are requested to date, execute and return the accompanying form of proxy to the Corporation's registrar and transfer agent, Valiant Trust Company, pursuant to the instructions noted therein, prior to 10:30 a.m., Calgary time, on October 6, 2014, or at least forty-eight (48) hours, excluding Saturdays, Sundays and statutory holidays, preceding any adjournment of the Meeting. Late proxies may be accepted or rejected by the Chairman of the Meeting in his discretion, and the Chairman is under no obligation to accept or reject any particular late proxy.

Your participation as a shareholder is very important to the Corporation. Please ensure your Common Shares are represented at the Meeting.

DATED at Calgary, Alberta, this 25<sup>th</sup> day of August, 2014.

**BY ORDER OF THE BOARD OF DIRECTORS**

(signed) "*Donald J. McCaffrey*"

---

Donald J. McCaffrey  
Chairman of the Board



## ZENITH EPIGENETICS CORP.

### MANAGEMENT INFORMATION CIRCULAR

**For the Annual Meeting of Shareholders  
to be held on Wednesday, October 8, 2014**

### PROXIES

#### Solicitation of Proxies

**This Management Information Circular is furnished in connection with the solicitation of proxies by the management of Zenith Epigenetics Corp.** (the "**Corporation**") for use at the Annual Meeting of the holders (the "**Shareholders**") of common shares (the "**Common Shares**") of the Corporation to be held on Wednesday, October 8, 2014, at the Calgary TELUS Convention Centre, The Glen Room 206, 120 – 9<sup>th</sup> Avenue SE, Calgary, Alberta at 10:30 a.m. (Calgary time) and at any adjournment thereof (the "**Meeting**"), for the purposes set forth in the accompanying Notice of Meeting. Only Shareholders of record at the close of business on August 25, 2014 (the "**Record Date**") are entitled to notice of, and to attend and vote at, the Meeting, unless a Shareholder has transferred any Common Shares subsequent to that date and the transferee Shareholder establishes ownership to the Common Shares and demands, not later than 10 days before the Meeting, that the transferee's name be included on the list of Shareholders.

#### Notice to Beneficial Holders of Common Shares

**The information set forth in this section is of significant importance to many Shareholders of the Corporation, as a substantial number of the Shareholders do not hold Common Shares in their own name.** Shareholders who do not hold their Common Shares in their own name (referred to herein as "**Beneficial Shareholders**") should note that only proxies deposited by Shareholders whose names appear on the records of the Corporation as the registered holders of Common Shares can be recognized and acted upon at the Meeting. If Common Shares are listed in an account statement provided to a Shareholder by a broker, then in almost all cases those Common Shares will not be registered in the Shareholder's name on the records of the Corporation. Such Common Shares will more likely be registered under the name of the Shareholder's broker or an agent of that broker. In Canada, the vast majority of such Common Shares are registered under the name of CDS & Co. (the registration name for The Canadian Depository for Securities Limited, which acts as nominee for many Canadian brokerage firms). Common Shares held by brokers or their nominees can only be voted (for or against resolutions) upon the instructions of the Beneficial Shareholder. Without specific instructions, the brokers/nominees are prohibited from voting Common Shares for their clients. The Corporation does not know for whose benefit the Common Shares registered in the name of CDS & Co. are held.

Applicable regulatory policy requires intermediaries/brokers to seek voting instructions from Beneficial Shareholders in advance of securityholders' meetings. Every intermediary/broker has its own mailing procedures and provides its own return instructions, which should be carefully followed by Beneficial Shareholders in order to ensure that their Common Shares are voted at the Meeting. Often, the form of proxy supplied to a Beneficial Shareholder by its broker is identical to the form of proxy provided to registered Shareholders; however, its purpose is limited to instructing the registered Shareholder how to vote on behalf of the Beneficial Shareholder. The majority of brokers now delegate responsibility for obtaining voting instructions from clients to Broadridge Financial Solutions, Inc. ("**Broadridge**"). Broadridge typically mails a scannable "voting instruction form" in lieu of the form of proxy. Beneficial Shareholders are requested to complete and return the voting instruction form to Broadridge by mail or facsimile. Alternatively, Beneficial Shareholders can call a toll-free telephone number or access Broadridge's dedicated voting website (each as noted on the voting instruction form) to deliver their voting instructions and vote the Common Shares held by them. Broadridge then tabulates the results of all instructions received and provides appropriate instructions respecting the voting of Common Shares to be represented at the Meeting. A Beneficial Shareholder receiving a voting instruction form cannot use that voting instruction form to vote Common Shares directly at the Meeting. The voting instruction form must be

returned as directed by Broadridge well in advance of the Meeting in order to have the Common Shares voted. Beneficial Shareholders who receive forms of proxies or voting materials from organizations other than Broadridge should complete and return such forms of proxies or voting materials in accordance with the instructions on such materials in order to properly vote their Common Shares at the Meeting.

Beneficial Shareholders who wish to appear in person and vote at the Meeting must appoint themselves as proxy by inserting their name in the blank space on the Form of Proxy or voting instruction form provided to them and return same to their broker (or the broker's agent) in accordance with the instructions provided by such broker.

Management of the Corporation does not intend to pay for intermediaries to forward to objecting beneficial owners under National Instrument 54-101 – *Communication with Beneficial Owners of Securities of a Reporting Issuer* the Meeting materials and Form 54-101F7 – Request for Voting Instructions Made by Intermediary, and in the case of an objecting beneficial owner, the objecting beneficial owner will not receive the Meeting materials unless the objecting beneficial owner's intermediary assumes the cost of delivery.

### **Notice-And-Access**

The Corporation has elected to use the "notice-and-access" provisions under National Instrument 54-101 *Communications with Beneficial Owners of Securities of a Reporting Issuer* for the Meeting in respect of the mailing of the Meeting materials, to the Beneficial Shareholders, but not in respect of the registered Shareholders. The notice-and-access provisions are a set of rules developed by the Canadian Securities Administrators that reduce the volume of materials required to be physically mailed to shareholders by allowing a reporting issuer to post its proxy-related meeting materials online.

The Corporation has also elected to use stratification procedures in relation to the use of the notice-and-access provisions. Stratification occurs when a reporting issuer using the notice-and-access provisions provides a paper copy of the management information circular and notice of meeting and, if applicable, a paper copy of the annual financial statements and related management's discussion and analysis, to some but not all of its shareholders. In relation to the Meeting, the Corporation's registered Shareholders will receive a paper copy of the Notice of Meeting, the Management Information Circular, a form of proxy and the annual financial statements and related management's discussion and analysis. All Beneficial Shareholders will receive a notice-and-access notification and a proxy or voting instruction form and only those Beneficial Shareholders who responded to the supplemental mail card pursuant to National Instrument 51-102 will receive a copy of the annual financial statements and related management's discussion and analysis.

### **Appointment and Revocation of Proxies**

Shareholders that cannot attend the Meeting in person are requested to complete, sign, date and return the accompanying form of proxy ("**Form of Proxy**") in the envelope provided. The instrument appointing a proxy shall be in writing and shall be executed by the Shareholder or his or her attorney authorized in writing or, if the Shareholder is a corporation, under its corporate seal or by an officer or attorney thereof duly authorized. In order to be effective, the proxy must be deposited at the office of the Corporation's transfer agent, Valiant Trust Company, 310, 606 – 4<sup>th</sup> Street SW, Calgary, Alberta, Canada, T2P 1T1, or by fax at 403-233-2857, not later than 48 hours (excluding Saturdays, Sundays and holidays) before the time for holding the Meeting.

**The persons named in the Form of Proxy are directors or officers of the Corporation. A person or corporation submitting the form of proxy has the right to appoint a person (who does not have to be a Shareholder) to be their representative at the Meeting, other than the persons designated in the Form of Proxy furnished by the Corporation. Such appointment may be exercised by inserting the name of the appointed representative in the blank space provided for that purpose. A Shareholder should notify the nominee of his or her appointment, obtain his or her consent to act as proxy and should instruct him or her as to how the Shareholder's Common Shares are to be voted.**

A Shareholder who has submitted a proxy may revoke it at any time prior to the exercise thereof. If a person who has given a proxy attends personally at the Meeting such person may revoke the proxy and vote in person. In addition to revocation in any other manner permitted by law, a proxy may be revoked by instrument in writing executed by the Shareholder or his or her attorney authorized in writing or, if the Shareholder is a corporation, under its corporate seal or by an officer or attorney thereof duly authorized, and deposited at the Corporation's registered office at 600, 815 - 8<sup>th</sup> Avenue SW, Calgary, Alberta, T2P 3P2, at any time prior to 4:30 p.m. (Calgary time) on the last business day preceding the day of the Meeting at which the proxy is to be used, or with the chairman of the Meeting on the day of the Meeting, and upon either of such deposits, the proxy is revoked.

### **Voting by Internet**

The Corporation's Shareholders may also use the internet site at [www.valianttrust.com](http://www.valianttrust.com) to transmit their voting instructions. Shareholders should have the form of proxy in hand when they access the web site. Shareholders will be prompted to enter their Control Number, which is located on the form of proxy. If Shareholders vote by internet, their vote must be received not later than 10:30 a.m. (Calgary time) on October 6, 2014 or 48 hours prior to the time of any adjournment of the Meeting. **The website may be used to appoint a proxy holder to attend and vote on a Shareholder's behalf at the Meeting and to convey a Shareholder's voting instructions. Please note that if a Shareholder appoints a proxy holder and submits their voting instructions and subsequently wishes to change their appointment, a Shareholder may resubmit their proxy and/or voting direction, prior to the deadline noted above. When resubmitting a proxy, the most recently submitted proxy will be recognized as the only valid one, and all previous proxies submitted will be disregarded and considered as revoked, provided that the last proxy is submitted by the deadline noted above.**

### **Persons Making the Solicitation**

**This solicitation is made on behalf of management of the Corporation.** The costs incurred in the preparation and mailing of the Form of Proxy, Notice of Meeting and this Management Information Circular and the solicitation of proxies will be borne by the Corporation. In addition to the use of mail, proxies may be solicited by personal interviews, or by other means of communication or by the directors, officers and employees of the Corporation, who will not be remunerated therefor.

### **Exercise of Discretion by Proxies**

The Common Shares represented by proxies in favour of management nominees will be voted or withheld from voting on any poll at the Meeting and where the Shareholder specifies a choice with respect to any matter to be acted upon, the Common Shares will be voted in accordance with the specification so made.

**In the absence of such specification, such Common Shares will be voted IN FAVOUR of the matters to be acted upon as set out herein. The persons appointed under the Form of Proxy furnished by the Corporation are conferred with discretionary authority with respect to amendments or variations of those matters specified in the Form of Proxy and Notice of Meeting and with respect to any other matters which may properly be brought before the Meeting. In the event that amendments or variations to matters identified in the Notice of Meeting or any other matters are properly brought before the Meeting, it is the intention of the persons designated in the enclosed Form of Proxy to vote in accordance with their best judgment on such matter. At the time of printing this Management Information Circular, the management of the Corporation knows of no such amendment, variation or other matter.**

### **Quorum**

The by-laws of the Corporation provide that a quorum of Shareholders is present at a meeting of shareholders of the Corporation if at least two persons are present in person or by proxy representing not less than five percent (5%) of the outstanding shares of the Corporation entitled to be voted at the meeting.

## VOTING SHARES AND PRINCIPAL HOLDERS THEREOF

The Corporation is authorized to issue an unlimited number of Common Shares and an unlimited number of Preferred Shares. As at the effective date of this Management Information Circular (the “**Effective Date**”), which is August 25, 2014, the Corporation has 90,973,188 Common Shares issued and outstanding and nil Preferred Shares issued and outstanding.

The Common Shares are the only shares entitled to be voted at the Meeting. Holders of Common Shares of record at the close of business on the Record Date are entitled to vote such Common Shares at the Meeting on the basis of one vote for each Common Share held except to the extent that, (a) the holder has transferred the ownership of any of his Common Shares after the Record Date, and (b) the transferee of those Common Shares produces properly endorsed share certificates, or otherwise establishes that he owns the Common Shares, and demands not later than (10) days before the day of the Meeting that his name be included in the list of persons entitled to vote at the Meeting, in which case the transferee will be entitled to vote his Common Shares at the Meeting.

Except as set forth below, to the knowledge of the directors and the executive officers of the Corporation, as at the Effective Date, no person or company beneficially owns or controls or directs, directly or indirectly, voting securities carrying 10% or more of the voting rights attached to any class of voting securities of the Corporation.

<b>Beneficial Owner</b>	<b>Number of Common Shares Held</b>	<b>Percentage of Outstanding Common Shares</b>
Eastern Capital Limited Cayman Islands	19,200,000	21.1%
NGN BioMed Opportunity II LP New York, U.S.A.	11,103,004	12.2%

## MATTERS TO BE ACTED UPON AT THE MEETING

### 1. **Presentation of Financial Statements**

The consolidated financial statements of the Corporation for the year ended April 30, 2014, together with the auditors' report on those financial statements, have been mailed to the registered Shareholders of the Corporation and those Beneficial Shareholders who responded to the Corporation's supplemental mail list card. These financial statements are also available on the internet on the Corporation's SEDAR profile at [www.sedar.com](http://www.sedar.com).

### 2. **Fixing the Number of Directors and Election of Directors**

The Articles of the Corporation provide that the minimum number of directors shall be three and the maximum number shall be 12. There are currently six directors. At the Meeting, Shareholders will be asked to set the board of directors of the Corporation (the “**Board**”) at six and to elect six directors to serve until the next annual general meeting, or until their respective successors have been elected or appointed. **Unless otherwise directed, the Common Shares of the Corporation represented by proxy in favour of management designees will be voted FOR the election of nominees herein listed.**

#### *Nominees for Election*

Management does not contemplate that any of the nominees will be unable to serve as a director. In the event that prior to the Meeting any vacancies occur in the slate of nominees herein listed, it is intended that discretionary authority shall be exercised by the person named in the proxy to vote the Common Shares

represented by proxy for the election of any other person or persons as directors unless the Shareholder has directed that the Common Shares be withheld from voting on the election of directors.

The directors of the Corporation are nominated by Shareholders of the Corporation at each annual meeting of shareholders. All directors serve until the next annual meeting or until a successor is elected or appointed, unless his position is earlier vacated. The Board currently consists of six directors, all of whom are standing for re-election. The name, residence, date of appointment, principal occupation, and number of Common Shares beneficially owned or over which control or direction is exercised directly or indirectly, with respect to each of the six nominees as directors of the Corporation is set forth below.

<u>Name and Residence</u>	<u>Director Since</u>	<u>Principal Occupation</u>	<u>Common Shares Beneficially Owned or Controlled or Directed as at Effective Date<sup>(1)</sup></u>
<b>Donald J. McCaffrey</b> Alberta, Canada	April 10, 2013	Chairman of the Corporation. President, CEO, Director and Secretary of Resverlogix Corp.	3,359,071
<b>Dr. Peter Johann</b> <sup>(3)(4)</sup> Heidelberg, Germany	April 10, 2013	Lead Director of the Corporation. Managing General Partner of NGN Capital LLC, a venture capital firm dedicated to health care investing. Director of Resverlogix Corp.	11,128,004 <sup>(5)</sup>
<b>Kelly McNeill</b> <sup>(2)(3)(4)</sup> Manitoba, Canada	April 10, 2013	Executive VP, Finance & Administration and CFO of IMRIS Inc., a biomedical company. Director of Resverlogix Corp.	10,000
<b>Dr. Eldon R. Smith</b> <sup>(2)(3)(4)</sup> Alberta, Canada	April 10, 2013	President and CEO, Eldon R. Smith & Associates Ltd., a private healthcare consulting company. Director of Canadian Natural Resources Ltd., an oil and gas producer; Aston Hill Financial Inc., a financial management company; Intellipharmaceuticals International Inc., a biotech/pharmaceuticals company; and Resverlogix Corp. Emeritus Professor of Medicine and Former Dean, Faculty of Medicine, University of Calgary.	6,000
<b>Kenneth Zuerblis</b> <sup>(2)</sup> Florida, U.S.A.	April 10, 2013	Certified Public Accountant. Director of Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, and Director of Resverlogix Corp.	Nil
<b>Dr. Julie Cherrington</b> California, U.S.A.	July 23, 2014	President and CEO of the Corporation since July 2014. President, CEO and a director of Pathway Therapeutics, Inc., a biotechnology company, from 2009 to 2013. President of Phenomix Corporation, a biotechnology company, from 2003 to 2009. VP Preclinical and Clinical Research of SUGEN, a biotechnology company, from 1998 to 2003. Director Virology of Gilead Sciences, a biotechnology company, from 1992 to 1998.	Nil

**Notes:**

- (1) Common Shares beneficially owned or over which control or direction is exercised, directly or indirectly, as at the Effective Date, is based upon the information furnished to the Corporation by the above individuals.
- (2) Directors who are currently members of the Corporation's Audit and Finance Committee. Mr. Zuerblis is the Chair.
- (3) Directors who are currently members of the Corporation's Corporate Governance and Nominating Committee. Dr. Smith is the Chair.
- (4) Directors who are currently members of the Corporation's Compensation and HR Committee. Mr. McNeill is the Chair.
- (5) Includes 11,103,004 Common Shares registered in the name of NGN BioMed Opportunity II LP, which are under the control or direction of Dr. Johann as Managing General Partner of NGN Capital LLC, the general partner of such Fund.

### *Cease Trade Orders or Bankruptcies and Sanctions*

No proposed director is as at the date hereof, or has been within ten years before the date hereof, a director or chief executive officer or chief financial officer of any company (including the Corporation) that, while he/she was acting in such capacity: (i) was the subject of a cease trade or similar order, or an order that denied the relevant company access to any exemption under securities legislation for a period of more than 30 consecutive days; or (ii) was subject to an event that resulted, after the director ceased to be a director or chief executive officer or chief financial officer, in the company being the subject of a cease trade or similar order or an order that denied the relevant company access to any exemption under securities legislation, for a period of more than 30 consecutive days.

In addition, no proposed director is as at the date hereof, or has been within ten years before the date hereof, a director or executive officer of any company (including the Corporation) that, while that person was acting in that capacity or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager, or trustee appointed to hold its assets. No proposed director has, within ten years before the date hereof, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the proposed director.

### **3. Appointment of Auditors**

KPMG LLP are the current auditors of the Corporation. At the Meeting, Shareholders will be requested to re-appoint KPMG LLP, Chartered Accountants, as the independent auditors of the Corporation to hold office until the next annual general meeting of the Shareholders and to authorize the Board to fix the auditors' remuneration.

**Unless otherwise directed, the Common Shares represented by proxies in favour of the management designees will be voted FOR the appointment of KPMG LLP, Chartered Accountants, of Calgary, Alberta, as auditors of the Corporation, to hold office until the next annual meeting of the Shareholders and to authorize the directors to fix their remuneration as such.**

## **EXECUTIVE COMPENSATION**

### **General**

The objectives of the Corporation's executive compensation program are designed to support an appropriate relationship between executive pay and the creation of shareholder value. The objectives of the program are as follows:

- To provide compensation comparable to similar companies and thereby enable the Corporation to attract and retain talented executives critical to the Corporation's long-term success.
- To align the interests of executives with long-term interests of Shareholders through stock option, RSU and restricted stock awards whose value over time depends upon the market value of the Common Shares;
- To motivate and retain key senior officers to achieve strategic business initiatives and reward them for their individual and team achievements.

The Corporation's executive compensation program is available to the Named Executive Officers of the Corporation which is defined by the securities legislation to mean each of the following individuals, namely: (i) the CEO; (ii) the Chief Financial Officer of the Corporation; (iii) each of the Corporation's three most highly compensated executive officers, or the three most highly compensated individuals acting in a similar

capacity, other than the CEO and the Chief Financial Officer, at the end of the most recently completed financial year whose total compensation was, individually, more than \$150,000 for that financial year; and (iv) each individual who would be a "Named Executive Officer" under (iii) above but for the fact that the individual was neither an executive officer of the Corporation, nor acting in a similar capacity, at the end of the most recently completed financial year (the "Named Executive Officer" or "NEO").

The Named Executive Officers of the Corporation for the year ended April 30, 2014 are:

Donald J. McCaffrey, President, Chief Executive Officer and Secretary  
A. Brad Cann, Chief Financial Officer  
Dr. Greg Wagner, Former Senior VP, Research & Development

### **Compensation Governance**

The Corporation's Board has established a Compensation and HR Committee comprised of independent directors. The purpose of the Compensation and HR Committee is to assist the Board in fulfilling its responsibilities by reviewing and making recommendations to the Board on its findings and conclusions on matters relating to the compensation of the NEOs and directors of the Corporation and its subsidiaries in the context of the budget, business plan and competitive environment of the Corporation; conducting and assisting in the regular reviews and appraisals of the Chief Executive Officer and other NEOs; ensuring appropriate succession plans are in place for the NEOs; and reviewing the Corporation's overall compensation policies and practices to ensure that the Compensation and HR Committee and the Board consider the implications of the risks associated with such policies and practices.

In fulfilling its mandate, the Compensation and HR Committee:

- annually reviews and recommends for approval to the Board the compensation packages for the CEO and the other NEOs, including short term and long term incentive plan grants and awards;
- annually reviews and recommends for approval to the Board the corporate goals, objectives and business performance measures which will be used in evaluating the CEO and the other NEOs;
- ensures that an effective succession plan for the Corporation's senior management team is in place and annually reviews such plan with the Board;
- pursuant to the terms of the Corporation's Option Plan and LTIP, recommends for approval to the Board the options or awards granted under such plans;
- pursuant to the terms of the Corporation's short term incentive plan for NEOs, recommends for approval to the Board the granting of the bonuses under such plan;
- annually reviews and ensures that compensation plans, in their design, structures and application have a clear link between pay and performance and do not encourage excessive risk taking;
- annually reviews and assesses compensation principles of, and compensation amounts payable by, appropriate comparator groups and recommends for approval to the Board any appropriate changes; and
- reviews and recommends to the Board the compensation to be paid to the Corporation's directors.

The terms of the compensation arrangements for each NEO (other than the Chief Executive Officer) are reviewed by the Chief Executive Officer with the Compensation and HR Committee. The terms of the Chief Executive Officer's compensation arrangements are reviewed by the Compensation and HR Committee in the absence of the Chief Executive Officer. All changes to the compensation arrangements of the NEOs are recommended for approval by the Compensation and HR Committee and approved by the Corporation's Board.

### *Composition of the Compensation and HR Committee*

The Compensation and HR Committee consists of three members: Kelly McNeill (as Chair), Dr. Peter Johann and Dr. Eldon Smith. All members are independent in accordance with National Instrument 52-110 - *Audit Committees*. Below are brief biographies of the Compensation and HR Committee members which illustrate their relevant experience.

#### *Kelly McNeill*

Mr. McNeill has first-hand experience with establishing, implementing and maintaining executive and employee compensation programs through his prior executive management positions with Resverlogix Corp., Haworth Ltd. and SMED International as well as with his current position as Vice President, Finance and Administration and Chief Financial Officer of IMRIS Inc. (listed on the TSX and NASDAQ). He is also the chair of the compensation committee of Resverlogix Corp. (a clinical stage biotech company listed on the TSX). He provides an important front-line perspective on the Corporation's Compensation and HR Committee and has knowledge and experience with current executive compensation requirements for both Canadian and US listed issuers.

#### *Dr. Peter Johann*

Dr. Johann is currently the Managing General Partner for NGN Capital and he serves on the compensation committees of Resverlogix Corp., Noxxon Pharma AG (a private clinical stage biotech company) and Exosome Diagnostics, Inc. (a private company developing molecular diagnostic tests for personalized medicine). In the past, he has also served on the compensation committees of Micromet Inc. and Horizon Pharma, Inc. (both listed on NASDAQ). Dr. Johann is knowledgeable in current executive compensation practices and disclosure requirements in connection with his past and current involvement with a number of compensation committees.

#### *Dr. Eldon Smith*

Dr. Smith is a physician and President and CEO of Eldon R. Smith and Associates Ltd. (a private healthcare consulting company) and was for many years involved in senior administration at the University of Calgary. From 1992 to 1997, Dr. Smith served as the Dean (Chief Executive Officer) of the Faculty of Medicine, where he was responsible for approximately 1,600 employees.

In addition to the Corporation, Dr. Smith also serves on the compensation committees of Resverlogix Corp., Canadian Natural Resources Limited (a TSX/NYSE company), Aston Hill Financial Inc. as chair of the committee (a TSX company), and Intellipharma International Inc. as chair of the committee (a TSX/NASDAQ company).

Dr. Smith is knowledgeable in current executive compensation practices and disclosure requirements in connection with his past and current involvement with a number of compensation committees.

### **Risk Management**

The combination of short term and long term incentive plans in the Corporation's compensation program ensures that a significant portion of each NEO's compensation is at risk annually. The balance between the short term and long term incentive plans aligns the NEO's interests with both the short and long term interests of the Shareholders and the Corporation's business strategy. It is, however, important to ensure that the Corporation's incentive plans do not result in an NEO taking actions that expose the Corporation to inappropriate or excessive risks or which would conflict with the Corporation's short term and long term interests. The Corporation believes that its compensation policies and practices have been structured to ensure that they do not encourage an NEO to expose the Corporation to inappropriate or excessive risks. Key components of the management of this risk include:

- All NEOs are compensated based on similar financial metrics and performance goals approved by the Board.

- Incentives are balanced between short term incentives and long term incentives which vest over time.
- Short term incentive programs for all employees (including the NEOs), while having different attributes, are subject to the same fundamental characteristics: payable only on the achievement of specified corporate and personal goals which have been defined at the beginning of a fiscal year.
- All short term incentive programs have clearly specified payout limits.

As a result of the steps taken to consider and mitigate the risks associated with the Corporation's compensation policies and practices, the Corporation has not identified any risks from such policies and practices which would be reasonably likely to have a material adverse effect on the Corporation.

### *Financial Instruments*

The Corporation does not have a policy that would prohibit a Named Executive Officer or director from purchasing financial instruments, including prepaid variable forward contracts, equity swaps, collars or units of exchange funds, that are designed to hedge or offset a decrease in market value of equity securities granted as compensation or held, directly or indirectly, by the Named Executive Officer or director, other than general provisions in the Corporation's trading policy which prohibit officers from short-selling and buying put options in respect of the Corporation's securities. However, management is not aware of any Named Executive or director purchasing such an instrument.

### **Benchmark Review**

During fiscal 2014, the Compensation and HR Committee, with assistance from the CEO and CFO, conducted an informal compensation review of publicly available data relating to the Corporation's peers' pay levels and practices, which the Corporation has used to compare its existing compensation program and assist with establishing compensation for the next fiscal year.

Following a detailed review, the Compensation and HR Committee recommended and the Board approved an executive and director compensation peer group consisting of Canadian biotech companies whose market capitalization ranged from \$40 million to \$250 million. Depending on the NEO's position and available comparative data, up to 11 companies were included in the comparator group, being:

- iCo Therapeutics Inc. (TSXV)
- AEterna Zentaris, Inc. (TSX/NASDAQ)
- Bioniche Inc. (TSX)
- Diamedica Inc. (TSXV)
- Immunovaccine, Inc. (TSXV)
- Cardiome Pharma Corp. (TSX/NASDAQ)
- Helix BioPharma Corp. (TSX)
- Oncolytics Biotech Inc. (TSX/NASDAQ)
- Resverlogix Corp. (TSX)
- Transition Therapeutics Inc. (TSX)
- Cangene Corporation (TSX)

Comparative statistics (including percentile rankings) on base salaries, bonus plans and security based incentive plans were provided in the review. The Corporation determined it would continue to use the median (50<sup>th</sup> percentile) range as its overall benchmark.

## Compensation Elements

The Corporation compensates its executive officers primarily through base salary, annual bonuses and long-term equity based incentives, being participation in the Option Plan and Long-Term Incentive Plan (the "LTIP"). In addition, the Corporation's NEOs participate in the Corporation's benefit programs, including life insurance and health and dental, on the same basis that such benefits are offered to all employees of the Corporation.

### 1. Base Salary

Base salary is the principal component of executive compensation. Base salary for NEOs reflects (i) the scope, complexity and responsibility of the role of the NEO; (ii) competitiveness with salary levels for similar positions at companies included in the market comparator group; (iii) the NEOs previous experience and performance; and (iv) the NEOs performance rating.

### 2. Short Term Incentive Plan - Annual Bonuses

The Corporation has a performance-based program that links the attainment of predetermined performance targets to operational and market-based short-term incentive pay targets. NEOs are eligible to receive a bonus of up to a percentage of base salary, which is paid on a sliding scale relative to the successful completion of the established performance objectives. The sliding scale corresponds to a maximum target level that is reviewed and set annually by the Compensation and HR Committee. The performance objectives are prepared by and proposed by the NEOs to the Compensation and HR Committee for analysis and review and are recommended for final approval to the Board. The President and CEO abstains from voting at the Board meeting on these matters.

The performance targets for the NEOs and other executive officers are established annually in connection with the achievement of goals and objectives for the Corporation in the following key areas: i) stakeholder management; ii) corporate development, including clinical advancement and science development; iii) financial performance, including achieving budgets, financial reporting and financing; and iv) innovation and learning.

### 3. Long-Term Equity Based Incentives

The Corporation operates an Option Plan and LTIP (as further detailed below) to provide its employees, consultants, officers and directors with a long-term incentive for high performance and commitment to the Corporation. Options granted under the Option Plan and RSUs and restricted stock granted under the LTIP vest over a period of time as designated by the Board.

The Corporation believes that participation by the NEOs in the Option Plan and LTIP aligns the interests of the NEOs with those of the Corporation's Shareholders, as the NEOs are rewarded for positive performance through share price appreciation. As a result of the vesting period for issued options, RSUs and restricted stock, participation by the NEOs in the Option Plan and LTIP focuses the NEOs on the long-term appreciation of the Corporation's share price.

In determining the number of options, RSU's and/or restricted stock to be granted to an NEO, the number and term previously granted, individual and team responsibilities and functions, position, individual performance and projected contribution are considered. Proposals for grants under the Option Plan and LTIP are reviewed and considered by the Compensation and HR Committee and recommended to the Board for final approval.

## **Option Plan**

### Purpose and Eligibility

The purpose of the Corporation's Option Plan is to afford individuals who provide services to the Corporation or any of its subsidiaries or affiliates, including directors, officers, employees, or service providers, an opportunity to obtain a proprietary interest in the Corporation by permitting them to purchase Common Shares of the Corporation and to aid in attracting, as well as retaining and encouraging the continued involvement of, such individuals with the Corporation.

Under the Option Plan the Board may, from time to time, grant options to purchase Common Shares to directors, officers, employees, consultants and other eligible service providers of the Corporation and its subsidiaries and affiliates, if any. The Option Plan is a "10% rolling plan" in that it continuously provides for the reservation of a number of Common Shares under the Option Plan, including other securities based compensation arrangements, equal to 10% of the Corporation's issued and outstanding Common Shares on an undiluted basis. Thus, the maximum number of Common Shares that may be reserved under the Option Plan and other securities based compensation plans will, from time to time, vary proportionately to the issued and outstanding share capital of the Corporation. Further, the Option Plan is a "reloading plan", meaning that when options under the Option Plan expire, are cancelled or are exercised, the number of Common Shares reserved for issuance under such expired, cancelled or exercised options automatically become eligible to be reallocated pursuant to new stock options under the Option Plan.

### Restrictions under the Option Plan

Restrictions on the participation of Insiders are included in the Option Plan, such that the aggregate number of Common Shares issuable under the Option Plan, combined with all Common Shares issuable under all other security based compensation arrangements, to insiders cannot exceed 10% of the issued and outstanding Common Shares at any time; and the number of Common Shares issued to insiders in aggregate, within any one-year period under the Option Plan and any other securities based compensation arrangement cannot exceed 10% of the issued and outstanding Common Shares. The number of Common Shares issuable under stock options granted to any eligible individual, within any one year period, under the Option Plan and any other securities based compensation arrangement, cannot exceed 5% of the issued and outstanding Common Shares of the Corporation, with the exception of a consultant, who may not receive options exercisable into a number of Common Shares in excess of 2% of the issued and outstanding Common Shares at the time of grant.

### Terms

The exercise price of the Common Shares subject to each option shall be determined by the Board at the time the option is granted. In no event shall such exercise price be lower than the volume weighted average trading price of the Common Shares on any stock exchange on which the Common Shares may be listed for the five trading days immediately preceding the applicable vesting date, rounded up to the nearest cent, or if the Common Shares are not listed on a stock exchange, the fair market value of a Common Share on the date immediately preceding the grant date as determined by the Board.

Subject to earlier termination as described below, each option and all rights thereunder granted pursuant to the Option Plan shall expire on the date determined by the Board, provided that the duration of an option shall not exceed 10 years. The Option Plan also incorporates a provision such that where the option would otherwise expire during, or within 10 business days following the last day of, a trading black out period implemented by the Corporation, the expiry date for such option will then become the 10<sup>th</sup> business day following such black-out period.

The Board may, in its sole discretion, determine the time during which options shall vest and the method of vesting, or that no vesting restrictions shall exist.

Vested options may be exercised no later than 30 days following the date the optionee ceases to be a director, officer, employee or consultant of the Corporation, provided that if the cessation of office, directorship, employment or consulting arrangement is by reason of death, vested options may be exercised by the personal representatives of the deceased within a maximum period of one year following such death, subject to the expiry date of such option. Notwithstanding the foregoing, the Board may in its discretion permit the exercise of options in such manner and on such terms as may be authorized by the Board, provided that an option may not be exercised after its expiry date.

Options may be transferred to certain permitted assigns of the optionee, including the optionee's spouse, an administrator acting on behalf or for the benefit of the optionee or his/her spouse, a holding entity of the optionee or his/her spouse and a RRSP or RRIF of the optionee or his/her spouse.

### Amendments

Terms of the Option Plan may be amended by the Board without approval of Shareholders as follows:

- (a) The Board may, at any time and from time to time, suspend or terminate the Option Plan or amend any of its provisions, provided that no such suspension, termination or amendment may be made without:
  - (i) obtaining any required approval of any regulatory authority or stock exchange; and
  - (ii) obtaining the consent or deemed consent of the relevant optionholder in the event that such amendment materially prejudices the rights of any optionholder under any option previously granted to the optionholder.
- (b) Without limiting the generality of paragraph (a) above, the Board may, without approval of Shareholders, make amendments to the Option Plan for any of the following purposes:
  - (i) changing the eligibility for and limitations on participation in the Option Plan;
  - (ii) changing the terms on which options may be granted and exercised including, without limitation, the provisions relating to exercise price, vesting, expiry, assignment and the adjustments to be made pursuant to certain events, as further described in the Option Plan;
  - (iii) making any addition to or deletion or alteration of the provisions of the Option Plan that are necessary to comply with applicable law or the requirements of any regulatory authority or stock exchange or that are reasonably necessary to allow optionholders to receive fair and favourable tax treatment under relevant tax legislation;
  - (iv) correcting or rectifying any ambiguity, defective provision, error or omission in the Option Plan; and
  - (v) changing the provisions relating to the administration of the Option Plan; provided that if any such amendment would lead to a significant or unreasonable dilution of the outstanding Common Shares or provide additional material benefits to insiders, approval of the holders of the outstanding Common Shares must be obtained.

The Board's discretion and authority to amend the Option Plan is wide in scope and the foregoing paragraph (i)-(v) are merely non-exhaustive examples of situations in which the Board may amend the Option Plan.

- (c) Under the Option Plan, the Board may, at any time and from time to time, without the approval of Shareholders, amend any term of any outstanding option (including, without limitation, the exercise price, vesting and expiry date of the option), provided that:
  - (i) any required approval of any regulatory authority or stock exchange is obtained;
  - (ii) the Board would have had the authority to initially grant the option under the terms as so amended; and
  - (iii) the consent or deemed consent of the optionholder is obtained if the amendment would materially prejudice the rights of the optionholder under the option.

Notwithstanding the foregoing, approval of Shareholders must be obtained for an amendment to the Option Plan that would increase the maximum number of Common Shares issuable under the Option Plan, and disinterested Shareholder approval must be obtained for an amendment to any stock option agreement that would reduce the exercise price or extend the expiry date of options granted to an insider.

## **LTIP**

### Purpose and Eligibility

The purpose of the LTIP is to assist the Corporation in attracting, retaining and motivating key employees, directors, officers and consultants of the Corporation and its subsidiaries and to more closely align the personal interests of such persons with Shareholders, thereby advancing the interests of the Corporation and its Shareholders and increasing the long-term value of the Corporation. The LTIP is available to: (i) current full-time or part-time employees or officers of the Corporation or an affiliate (“Employee Participants”); (ii) directors who are not officers or employees of the Corporation or an affiliate (“Director Participants”); and (iii) an individual or consultant company providing services to the Corporation or an affiliate under written agreement (“Consultant Participant”). For the purposes of the LTIP and this Information Circular, a “Participant” shall mean an Employee Participant, Director Participant or a Consultant Participant.

### Administration

The LTIP is administered by the Board or, upon delegation by the Board, by a committee of the Board (the “Committee”). The Board has delegated the administration of the LTIP to the Corporation’s Compensation and HR Committee.

The Committee determines the Participants to whom awards are to be made, determines the type, size, terms and conditions of awards, determines the prices (if any) to be paid for awards, interprets the LTIP, adopts, amends and rescinds administrative guidelines and other rules and regulations relating to the LTIP, and makes all other determinations and takes all other actions it believes are necessary or advisable for the implementation and administration of the LTIP. The day-to-day administration of the LTIP may be delegated to a trustee appointed to administer the LTIP or to such officers and employees of the Corporation as the Committee determines.

### Restricted Share Units

The LTIP provides that the Committee may, from time to time and in its sole discretion, grant awards of restricted share units (“RSUs”) to any Participant. RSUs are not Common Shares, but rather represent a right to receive at a future date Common Shares of the Corporation. All grants of RSUs are evidenced by an award agreement. The award agreement contains such provisions as are required by the LTIP and any other provisions the Committee may direct.

The Committee has the authority to make receipt of Common Shares under the RSUs conditional upon the expiry of a time-based vesting period, the attainment of specified performance goals or such other factors

as the Committee may determine in its discretion. The duration of the vesting period and other vesting terms applicable to a grant of RSUs shall be determined at the time of the grant by the Committee provided that such vesting period shall be a minimum of one year and a maximum of three years in duration.

Upon expiry of the applicable vesting period or at such later date as may be otherwise specified in the award agreement, the RSUs shall be redeemed and a share certificate representing the Common Shares deliverable pursuant to the RSUs shall be registered in the name of the Participant or as the Participant may direct, subject to applicable securities laws.

Actual issuance of Common Shares underlying the RSUs shall occur as soon as practicable following the applicable vesting date(s) specified in the award agreement and the Participant's satisfaction of any required tax withholding obligations, but in no event later than: (i) 60 days following the vesting date for a Participant resident in the United States; or (ii) the earlier of: (a) 60 days following the applicable vesting date; and (b) December 15 of the third calendar year following the year of service for which the RSU was granted for a Participant resident in Canada.

RSU Awards shall be settled in Common Shares, unless the Corporation offers the Participant the right to receive cash in lieu of Common Shares and the Participant, in its discretion, so elects. In this case, the cash value of the Common Shares would be determined based on the volume weighted average trading price of the Common Shares on any stock exchange on which the Common Shares may be listed for the five trading days immediately preceding the applicable vesting date, rounded up to the nearest cent, or if the Common Shares are not listed on a stock exchange, the fair market value of a Common Share on the date immediately preceding the vesting date as determined by the Board.

Except as otherwise determined by the Committee, upon a Termination Date (as defined in the LTIP) during the applicable vesting period, all applicable RSUs at such time not yet vested shall be forfeited and reacquired by the Corporation.

#### Restricted Stock

The Committee may, from time to time, grant Participants resident in the United States, subject to the terms and conditions of the LTIP and any additional terms and conditions determined by the Committee, awards of Common Shares of the Corporation subject to certain restrictions imposed by the Committee ("Restricted Stock" and together with RSUs, an "Award"). All grants of Restricted Stock are evidenced by an award agreement. The award agreement contains such provisions as are required by the LTIP and any other provisions the Committee may direct.

The Committee has the authority to make the lapse of restrictions applicable to Restricted Stock conditional upon the expiry of a time-based vesting period, the attainment of specified performance goals or such other factors as the Committee may determine in its discretion. The duration of the vesting period and other vesting terms applicable to a grant of Restricted Stock shall be determined at the time of the grant by the Committee provided that such vesting period shall be a minimum of one year in duration.

Common Shares of Restricted Stock shall be subject to such restrictions as the Committee may impose (including, without limitation, forfeiture conditions, transfer restrictions or a restriction on, or prohibition against, the right to receive any dividend or other right or property with respect thereto), which restrictions may lapse separately or in combination at such time or times, in such instalments or otherwise as the Committee may deem appropriate.

A trustee appointed by the Corporation shall hold share certificates registered in the name of each Participant granted Restricted Stock under the LTIP. The share certificates shall bear a legend referring to the award agreement and the possible forfeiture of such shares of Restricted Stock.

Except as otherwise determined by the Committee, upon a Termination Date during the applicable vesting period, all applicable Common Shares of Restricted Stock at such time not yet vested shall be forfeited and reacquired by the Corporation.

### Number of Shares Reserved for Issuance under the LTIP

The Corporation may fulfill its obligations to deliver Common Shares under the LTIP by, at its option, either (i) issuing Common Shares from treasury to the Participant, or (ii) directing the Plan Trustee (which is an independent trust company selected by the Corporation to acquire Common Shares in the market at the direction of the Corporation for the purpose of the LTIP) to deliver Common Shares to the Participant.

The aggregate number of Common Shares of the Corporation which may be issued from treasury under the LTIP, together with shares reserved for issuance under all of the Corporation's other security-based compensation arrangements, which includes the Option Plan, shall not exceed 10% of the Corporation's issued and outstanding Common Shares on a non-diluted basis. The maximum number of Common Shares that may be reserved under the LTIP will, from time to time, vary proportionately to the issued and outstanding share capital of the Corporation. Further, when Awards under the LTIP vest and are redeemed, expire or are forfeited, surrendered, cancelled or terminated, the number of Common Shares under such Awards automatically become available to be made the subject of new Awards under the LTIP. The LTIP is an unfunded plan and any obligations of the Corporation under the LTIP are unsecured.

### Limitations on Issuance to Insiders and Director Participants

The total number of Common Shares issuable from treasury to insiders of the Corporation at any time and issued from treasury to insiders of the Corporation within any one-year period under the LTIP, together with any other security-based compensation arrangements of the Corporation, shall not exceed 10% of the issued and outstanding Common Shares of the Corporation on a non-diluted basis.

### Treatment on Termination

*Death, Disability and Retirement:* Except as otherwise determined by the Committee, where a Participant's employment or term of office or engagement with the Corporation or an affiliate terminates by reason of the Participant's death, disability or retirement then, unless otherwise determined by the Committee, any Awards that are not yet vested will be immediately forfeited to the Corporation at the Termination Date and such Participant shall cease to be eligible under the LTIP. In the case where a Participant has died, any Awards held by the Participant that have vested as of the Termination Date will enure to the benefit of the Participant's heirs, executors and administrators.

*Voluntary Resignation:* Except as otherwise determined by the Committee, where a Participant's employment or term of office or engagement terminates by reason of a Participant's resignation, then any Awards held by the Participant that are not yet vested at the Termination Date are immediately forfeited to the Corporation on the Termination Date.

*Termination without Cause:* Except as otherwise determined by the Committee, where a Participant's employment or term of office or engagement terminates by reason of termination by the Corporation or an affiliate without cause (as determined by the Committee in its discretion) (whether such termination occurs with or without any or adequate notice or reasonable notice, or with or without any or adequate compensation in lieu of such notice), then any Awards held by the Participant that are not yet vested at the Termination Date are immediately forfeited to the Corporation on the Termination Date.

*Termination for Cause:* Except as otherwise determined by the Committee, where a Participant's employment or term of office or engagement is terminated by the Corporation or an affiliate for cause (as determined by the Committee in its discretion), or, in the case of a Consultant Participant, for breach of contract (as determined by the Committee in its discretion), then any Awards held by the Participant at the Termination Date (whether or not vested) are immediately forfeited to the Corporation on the Termination Date.

*Termination of Director for other than Death or Disability:* Except as otherwise determined by the Committee, where a Director Participant's term of office terminates for any reason other than death or

disability of the Director Participant, the Committee or the Board may, in its discretion, at any time prior to or within 30 days following the Termination Date, provide for the vesting of any or all Awards held by a Director Participant on the Termination Date.

*Change of Employment Agreement:* Unless the Committee, in its discretion, otherwise determines, at any time and from time to time, Awards are not affected by a change of employment arrangement within or among the Corporation or an Affiliate for so long as the individual continues to be an eligible Participant.

*Discretion to Accelerate Vesting:* The Committee may, in its discretion, at any time prior to or following the retirement, death, disability or termination of employment of a Participant, permit the acceleration of vesting of any or all Awards, all in the manner and on the terms authorized by the Committee, provided that the Committee's discretion to accelerate vesting where there has been a change of control is limited to only those circumstances described below.

#### Change in Control

Unless otherwise determined by the Committee or the Board at or after the date of grant, if a Participant ceases to be a director, officer, employee or consultant of the Corporation or its subsidiaries within 12 months following a Change in Control (as defined in the LTIP) for any reason other than for cause, voluntary resignation, retirement, death, or disability, each Award held by that Participant that is not fully vested on the date at which such person ceases to be a director, officer, employee or consultant shall become free of all restrictions, conditions and limitations and become fully vested.

#### Share Capital Adjustments

The Board shall have the discretion to authorize such steps to be taken as it may consider to be equitable and appropriate in the event of any Share Reorganization, Corporate Reorganization or Special Distribution (all as defined in the LTIP), including the acceleration of vesting in order to preserve proportionately the rights, value and obligations of the Participants holding Awards in the circumstances or the Board otherwise determines that it is appropriate.

#### Amendments

Subject to the rules, regulations and policies of any stock exchange on which the Corporation's Common Shares may be trading and applicable law, the Committee may, without notice or shareholder approval, at any time or from time to time, make amendments to the LTIP or a specific Award that it may deem necessary, including without limitation, amendments for the purposes of: (i) altering, extending or accelerating the terms of vesting applicable to any Award or group of Awards; (ii) making any amendments to the general vesting provisions of an Award; (iii) accelerating the expiry date of conditions applicable to an Award; (iv) making any amendments to the provisions of the LTIP that relate to termination, (v) making any amendment to provide covenants of the Corporation in order to protect Participants; (vi) making any amendments not inconsistent with the LTIP as may be necessary or desirable with respect to matters or questions which, in the good faith opinion of the Board, having in mind the best interests of the Participants, it may be expedient to make, including amendments that are desirable as a result of changes in law; (vii) making any amendments for the purposes of curing or correcting any ambiguity or defect or inconsistent provision or clerical omission or mistake or manifest error in the LTIP; (viii) making any amendments to any definitions in the LTIP; (ix) effecting amendments respecting administration of the LTIP; and (x) making amendments of a "housekeeping" or ministerial nature.

Certain amendments under the LTIP may not be made without shareholder approval, and these include: (i) amendments to the LTIP that would increase the number of Common Shares issuable from treasury under the LTIP in general, or the number of Common Shares issuable from treasury to insiders under the LTIP, (ii) amendments to any amending provision in the LTIP; (iii) amendments to the LTIP to include a form of financial assistance to Participants; and (iv) amendments required to be approved by shareholders under applicable law.

In addition, certain amendments under the LTIP may not be made without disinterested shareholder approval, and these include but are not limited to: (i) amendments that could result at any time in the number of Common Shares reserved for issuance from treasury to an insider under the LTIP exceeding 10% of the Corporation's issued and outstanding Common Shares; (ii) amendments resulting in any extension of the term of any award under the LTIP to an insider other than the extension of awards expiring during a black-out period or during a black-out expiration term; and (iii) amendments required to be approved by disinterested shareholders under applicable law.

### Performance Goals

Awards of RSUs and Restricted Stock under the LTIP may be made subject to the attainment of certain performance goals as may be set by the Committee at the time of grant.

### Non-Transferability of Awards

Unless the Committee otherwise determines, awards granted under the LTIP may only be redeemed during the lifetime of the Participant by such Participant personally, provided that any Awards held by a Participant that have vested at the Termination Date will enure to the benefit of the Participant's heirs, executors and administrators. No assignment or transfer of Awards, whether voluntary, involuntary, by operation of law or otherwise, vests any interest or right in such Awards whatsoever in any assignee or transferee. Immediately upon any assignment or transfer, or any attempt to make the same, such Awards will terminate and be of no further force or effect.

### **Summary Compensation Table**

The following table sets forth all compensation paid, payable, awarded, granted, given, or otherwise provided, directly or indirectly, by the Corporation, or a subsidiary of the Corporation, in Canadian dollars, to the Corporation's NEO's for the most recently completed financial year, as the Corporation began operations effective June 3, 2013.

<u>Name and Principal Position</u>	<u>Year ended</u>	<u>Salary (\$)</u>	<u>Share-based awards<sup>(1)</sup> (\$)</u>	<u>Option-based awards<sup>(1)</sup> (\$)</u>	<u>Non-equity incentive plan compensation (\$)</u>		<u>Pension Value (\$)</u>	<u>All other compensation<sup>(2)</sup> (\$)</u>	<u>Total compensation (\$)</u>
					<u>Annual incentive plans (\$)</u>	<u>Long-term incentive plans (\$)</u>			
<b>Donald J. McCaffrey</b> <sup>(3)(4)(5)</sup> President, CEO and Secretary	2014 April 30	Nil	57,942	145,558	Nil	N/A	Nil	Nil	203,500
<b>A. Brad Cann</b> Chief Financial Officer <sup>(6)</sup>	2014	Nil	17,146	25,460	Nil	N/A	Nil	Nil	42,606
<b>Dr. Greg Wagner</b> <sup>(7)(8)(9)</sup> Former Senior VP, Research & Development	2014	Nil	24,016	40,120	Nil	N/A	Nil	Nil	64,136

**Notes:**

(1) Share-based awards and Option-based awards amounts are non-cash fair value estimates of options granted during the year, calculated using the Modified Black-Scholes pricing model, whereby the fair value of stock options above is determined on the grant date. The estimated fair market values of the stock options granted on June 3, 2013 ranged from \$0.09 to \$0.22. The values were based on the following key assumptions: terms ranging from 0.3 to 5 years, expected lives ranging from 0.3 to 4.2 years, exercise prices ranging from \$0.13 to \$0.33, volatility ranging from 60% to 89%, a fair market value of the Corporation's shares of \$0.38, a risk-free rate ranging from 1.0% to 1.4% and expected dividend yield of 0%. For accounting purposes, the

compensation expense noted above would be amortized over the vesting period of the stock options. The Modified Black-Scholes model is an industry accepted valuation method.

- (2) Except as set forth above, the value of perquisites and other personal benefits received by each NEO was not in aggregate worth \$50,000 or more, or worth 10% or more of a NEOs total salary for each financial year.
- (3) Mr. McCaffrey is a member of the Corporation's Board; however he did not receive any additional compensation for acting as a director during fiscal year 2014.
- (4) Mr. McCaffrey resigned as President, CEO and Secretary of the Corporation on July 23, 2014 and became Chairman of the Board.
- (5) The Corporation paid fees to Resverlogix for services during the year ended April 30, 2014. Resverlogix paid a salary of \$404,600 to Mr. McCaffrey (of which \$165,178 was attributable to the Corporation). In addition, Resverlogix paid bonuses of \$96,497 to Mr. McCaffrey (of which \$51,143 was attributable to the Corporation) for the year ended April 30, 2014.
- (6) The Corporation paid fees to Resverlogix for services during the year ended April 30, 2014. Resverlogix paid a salary of \$241,680 to Mr. Cann (of which \$98,666 was attributable to the Corporation). In addition, Resverlogix paid bonuses of \$34,742 to Mr. Cann (of which \$18,413 was attributable to the Corporation) for the year ended April 30, 2014.
- (7) The Corporation paid fees to Resverlogix for services during the year ended April 30, 2014. Resverlogix paid a salary of \$372,787 to Dr. Wagner (of which \$336,319 was attributable to the Corporation). In addition, Resverlogix paid a termination benefit of \$90,303 to Dr. Wagner (of which \$87,593 was attributable to the Corporation).
- (8) Amounts paid to Dr. Wagner were paid in United States Dollars and for purposes of the above disclosure converted to Canadian Dollars based on an average exchange rate of 1.0602 in 2014.
- (9) Dr. Wagner's employment was terminated on April 15, 2014.

### Incentive Plan Awards for NEOs

#### *Outstanding Share-based Awards and Option-based Awards*

The following table sets forth, for each NEO, all option-based and share-based awards outstanding as at April 30, 2014.

Name	Option-based Awards <sup>(1)</sup>				Share-based Awards <sup>(2)</sup>		
	Number of securities underlying unexercised options (#)	Option exercise price <sup>(3)</sup> (\$)	Option expiration date	Value of unexercised in-the-money options <sup>(4)</sup> (\$)	Number of shares or units of shares that have not vested (#)	Market or payout value of share-based awards that have not vested (\$)	Market or payout value of vested share-based awards not paid out or distributed (\$)
Donald J. McCaffrey	100,000	0.24	Aug. 6/15	124,542	85,850	38,469	46,938
	286,300	0.15	Jun. 14/16				
	115,600	0.13	May 30/17				
	77,400	0.33	May 29/18				
A. Brad Cann	26,000	0.15	Jun. 14/16	13,126	25,200	11,292	13,981
	33,800	0.13	May 30/17				
	22,800	0.33	May 29/18				
Dr. Greg Wagner	49,000	0.26	Feb. 23/15	43,009	34,100	15,280	20,120
	87,000	0.15	Jun. 14/16				
	49,400	0.13	May 30/17				
	28,700	0.33	May 29/18				

**Notes:**

- (1) All options granted to the NEOs have been granted pursuant to the Corporation's Option Plan. See "SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS" elsewhere in this Information Circular.
- (2) Share-based awards pursuant to the Corporation's LTIP.
- (3) Options granted and exercise prices determined in accordance with the terms of a plan of arrangement amongst the Corporation, Zenith Epigenetics Corp. and RVX Therapeutics Inc. made effective June 3, 2013.
- (4) The fair value of the Corporation's Common Shares on April 30, 2014, as determined by the Board, was \$0.45 per share.

#### *Incentive Plan Awards – Value Vested or Earned During the Year*

The following table sets forth, for each NEO, the value vested or earned on all option-based awards, share-based awards, and non-equity incentive plan compensation during the financial year ended April 30, 2014.

Name	Option-based Awards – Value vested during the year <sup>(1)</sup> (\$)	Share-based Awards – Value vested during the year <sup>(1)</sup> (\$)	Non-equity incentive plan compensation – value earned during the year <sup>(2)</sup> (\$)
Donald J. McCaffrey	136,299	39,805	51,143
A. Brad Cann	19,805	11,856	18,413
Dr. Greg Wagner	32,065	17,062	Nil

**Notes:**

- (1) In June 2013, stock options and RSU's vested for the NEOs listed above. The fair value of the Corporation's Common Shares was \$0.38 in June 2013, as determined by the Board.
- (2) Bonuses earned under the Corporation's non-equity incentive plan (see "Compensation Elements" in this Information Circular) for fiscal 2014 were paid subsequent to year end to the NEOs.

**Management Contracts**

Pursuant to the Assignment and Services Agreement dated June 3, 2013 and effective May 1, 2012 between the Corporation and Resverlogix Corp. ("Resverlogix"), a biotechnology issuer listed on the Toronto Stock Exchange that has certain common directors and officers with the Corporation, the Corporation engaged Resverlogix to perform services on its behalf. As consideration for the services, the Corporation pays Resverlogix service fees for salary and other compensation related costs allocated to the services and reimbursable expenses incurred by the Corporation. In addition, pursuant to a Management Services Agreement dated June 3, 2013 between the Corporation and Resverlogix, the Corporation engaged Resverlogix to perform all management and administrative services pertaining to the Corporation as required. The Corporation pays Resverlogix a management fee based on the cost of Resverlogix personnel and the proportionate time worked on behalf of the Corporation.

**Termination and Change of Control Benefits**

As at April 30, 2014, Resverlogix had in place executive employment agreements with each of Mr. McCaffrey, Mr. Cann, and Dr. Wagner, all of which include certain termination and change of control benefits, which are described below. The employment agreements are reviewed annually by the Compensation and HR Committee of Resverlogix.

In the event that Mr. McCaffrey and Mr. Cann were terminated by Resverlogix for any reason other than for cause, disability, death, and voluntary termination, the Corporation would pay Resverlogix a management fee based on the proportionate time that Mr. McCaffrey and Mr. Cann had worked on behalf of the Corporation.

Donald J. McCaffrey

Mr. McCaffrey's employment agreement extends indefinitely, unless terminated by either party in accordance with the terms of the agreement. In the event of (i) a change of control, or (ii) for termination other than for cause, disability, death and voluntary termination, the President and CEO is entitled to severance equal to five months of base salary plus one month of base salary for each completed year of service subsequent to October 2, 2013, up to a total maximum of 18 months base salary, plus all accrued but unpaid bonuses. The agreement also provides for a 12 month non-competition clause following the termination of the agreement.

On July 23, 2014, Mr. McCaffrey was appointed as Chairman of the Board and ceased acting as President and CEO of the Corporation.

A. Brad Cann

Mr. Cann's employment agreement extends indefinitely, unless terminated by either party in accordance with the terms of the agreement. In the event of (i) a change of control, or (ii) for termination other than for

cause, disability, death, and voluntary termination, the CFO is entitled to severance equal to 12 months base salary, plus all accrued but unpaid bonuses.

Dr. Greg Wagner

Dr. Wagner's employment with Resverlogix was terminated (without cause) effective April 15, 2014. In connection with his termination, Dr. Wagner received severance equal to three months of base salary and the Board approved the continuation of his previously granted stock options and restricted stock under their original expiry and vesting terms.

Estimated Incremental Payment Obligations at April 30, 2014

The estimated incremental payment obligations of the Corporation related to the termination entitlements set forth above for each of the NEO's, assuming that the triggering event took place on April 30, 2014, are as follows:

<b>Named Executive Officer</b>	<b>(\$)<sup>(1)</sup></b>
Donald J. McCaffrey	147,453
A. Brad Cann	149,365
Dr. Greg Wagner	Nil

**Notes:**

(1) The severance amounts are based on a 50% allocation to the Corporation and a 50% allocation to Resverlogix.

The Board may in its discretion provide that all unvested options and LTIP awards issued to the NEOs vest upon the occurrence of a change of control in accordance with the provisions of the Corporation's Option Plan and LTIP. The value of unvested options held by such NEOs as at April 30, 2014 was \$46,842. The value of unvested LTIP awards held by such NEO's as at April 30, 2014 was \$65,041.

**Director Compensation**

Beginning October 1, 2013 until April 30, 2014, the Corporation paid the following fees to directors of the Corporation for services rendered in their capacity as directors.

Annual Fee for a Director	\$ 5,000
Additional Annual Fee for Chair of the Board	\$ 5,000
Additional Annual Fee for Committee Chairs	\$ 2,667
Meeting Fee for Board Meetings	\$ 400
Additional Meeting Fee for Chair of the Board	\$ 400
Meeting Fee for Committee Meetings	\$ 283
Additional Meeting Fee for Committee Chairs	\$ 283

Directors' fees are reviewed and considered at least annually by the Compensation and HR Committee.

Expenses that are incurred by each director related to attendance at meetings of the Board or committees thereof are reimbursed.

By policy, management directors are not paid an annual fee or a meeting fee.

During the financial year ended April 30, 2014, the directors of the Corporation were paid aggregate compensation of \$192,444.



Name	Option-based Awards <sup>(1)</sup>				Share-based Awards		
	Number of securities underlying unexercised options (#)	Option exercise price <sup>(2)</sup> (\$)	Option expiration date	Value of unexercised in-the-money options <sup>(3)</sup> (\$)	Number of shares or units of shares that have not vested (#)	Market or payout value of share-based awards that have not vested (\$)	Market or payout value of vested share-based awards not paid out or distributed (\$)
Kenneth Zuerblis	150,000	0.40	Oct. 7/15	20,780	N/A	N/A	N/A
	30,000	0.15	Jun. 14/16				
	30,000	0.14	May 1/17				
	30,000	0.32	May 6/18				
Dr. Eldon R. Smith	75,000	0.21	Dec. 24/15	31,422	N/A	N/A	N/A
	30,000	0.15	June 14/16				
	30,000	0.14	May 1/17				
	30,000	0.32	May 6/18				

**Notes:**

- (1) All options granted to the directors have been granted pursuant to the Corporation's Option Plan. See "SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS" elsewhere in this Information Circular.
- (2) Options granted and exercise prices determined in accordance with the terms of a plan of arrangement amongst the Corporation, Zenith Epigenetics Corp. and RVX Therapeutics Inc. made effective June 3, 2013.
- (3) The fair value of the Corporation's Common Shares on April 30, 2014, as determined by the Board, was \$0.45.
- (4) In connection with Mr. Higgins' resignation from the Board on February 11, 2014, the Board approved the continuation of his previously granted stock options under their original expiry and vesting terms.

**Incentive Plan Awards to Directors – Value Vested or Earned During the Year**

The following table sets forth for each director, other than Mr. McCaffrey as NEO, the value vested or earned on all option-based awards during the financial year ending April 30, 2014. Directors of the Corporation do not participate in any share-based awards or non-equity incentive plans of the Corporation.

Name	Option-based Awards – Value vested during the year <sup>(1)</sup> (\$)	Share-based Awards – Value vested during the year (\$)	Non-equity incentive plan compensation – value earned during the year (\$)
Dr. Peter Johann	17,500	N/A	N/A
Arthur Higgins	34,500	N/A	N/A
Kenneth Zuerblis	10,500	N/A	N/A
Dr. Eldon R. Smith	23,250	N/A	N/A
Kelly McNeill	10,500	N/A	N/A

**Notes:**

- (1) In June 2013, stock options vested for all the directors listed above. The fair value of the Corporation's Common Shares was \$0.38 in June 2013, as determined by the Board.

**SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS**

The following table sets forth securities of the Corporation that are authorized for issuance under equity compensation plans as at the end of the Corporation's most recently completed financial year.

Plan Category	Number of Common Shares to be issued upon exercise of outstanding options, warrants and rights (a)	Weighted-average exercise price of outstanding options, warrants and rights (b)	Number of Common Shares remaining available for issuance under equity compensation plans (excluding securities reflected in column a)
Equity compensation plans approved by securityholders <sup>(3)</sup>	4,318,238 <sup>(1)</sup>	\$0.20 <sup>(1)</sup>	4,288,063 <sup>(2)</sup>
Equity compensation plans not approved by securityholders	Nil	Nil	Nil
<b>Total</b>	<b>4,318,238</b>	<b>\$0.20</b>	<b>4,288,063</b>

**Notes:**

- (1) 3,621,637 stock options approved by securityholders and 696,600 restricted share units approved by securityholders. The weighted average exercise price of the 3,621,638 stock options was \$0.23. The restricted share units are subject to vesting criteria but do not require payment of an exercise price.
- (2) The aggregate number of Common Shares that may be reserved for issuance from treasury under the Option Plan and the LTIP shall not exceed 10% of the issued and outstanding shares of the Corporation. At April 30, 2014, the Corporation had 86,063,005 Common Shares issued and outstanding.
- (3) For a complete description of the material features of the Option Plan and LTIP, see "EXECUTIVE COMPENSATION – Option Plan" and "EXECUTIVE COMPENSATION – LTIP"

### AUDIT COMMITTEE INFORMATION

National Instrument 52-110 *Audit Committees* ("**NI 52-110**") requires the Corporation, as a venture issuer, to disclose annually certain information concerning the constitution of its Audit Committee and its relationship with its independent auditors, as set forth in the following discussion.

#### Audit and Finance Committee Charter

The Corporation's Audit and Finance Committee is governed by an Audit and Finance Committee Charter, the text of which is attached as Appendix A to this Circular.

#### Composition of the Audit and Finance Committee

The Audit and Finance Committee is currently comprised of three individuals, all of whom are financially literate and each of whom is an independent director as determined in accordance with NI 52-110. The current members of the Audit and Finance Committee are Mr. Zuerblis (Chair), Dr. Smith and Mr. McNeill.

#### Relevant Education and Experience

The following relevant education and experience of the members of the Audit and Finance Committee have been used in assessing their financial literacy:

##### Kenneth Zuerblis

Mr. Zuerblis received a BS in Accounting and is a Certified Public Accountant with nearly 30 years of experience, has held senior financial positions with three publicly-traded companies and has held directorships with numerous organizations. Mr. Zuerblis served as Executive Vice President and Chief Financial Officer of Savient Pharmaceuticals, Inc. from 2011 to 2012. Prior to joining Savient, Mr. Zuerblis served as Chief Financial Officer and Senior Vice President at ImClone Systems from 2008 through 2009. From 1994 through 2005, Mr. Zuerblis served as Chief Financial Officer of Enzon Pharmaceuticals Inc., and held the position of Corporate Controller from 1991 through 1994. Mr. Zuerblis began his career at KPMG, LLP in 1982 where he held management positions of increasing responsibility over a 10 year period. Mr. Zuerblis currently serves on the board of directors and audit committees of Stemline Therapeutics, Inc. and Resverlogix Corp.

### Kelly McNeill

Mr. McNeill holds a Masters of Accountancy and a Bachelor of Commerce (Honours), and is a Chartered Accountant with over 20 years of experience. Mr. McNeill has served as Executive Vice President, Finance and Administration, Chief Financial Officer and Secretary of IMRIS Inc. since 2009. From 2006 to 2009, Mr. McNeill was Chief Financial Officer of Resverlogix Corp. Prior thereto, Mr. McNeill held senior financial positions with two multinational companies. Mr. McNeill currently serves on the board of directors and audit committee of Resverlogix Corp.

### Dr. Eldon R. Smith

Dr. Smith is a physician and President and CEO of Eldon R. Smith and Associates Ltd. (a private healthcare consulting company), and was for many years involved in senior administration at the University of Calgary. From 1992 to 1997, Dr. Smith served as the Dean (Chief Executive Officer) of the Faculty of Medicine, where he was responsible for approximately 1,600 employees and an annual budget of more than \$100 million.

Dr. Smith has also served as the Chairman of a publicly listed company (TSX and NASDAQ) and over the past 15 years has served on the audit committees of seven (7) publicly traded companies in Canada and the USA. Dr. Smith currently serves on the board of directors of Canadian Natural Resources Ltd (TSX/NYSE) (since 1997); is lead director and member of the audit committee of Aston Hill Financial Inc. (since 2005) (TSX); the board of directors (since 2009) and a member of the audit committee of Intellipharmaceutics International Inc. (TSX/NASDAQ); and the board of directors (since 2010) and a member of the audit committee of Resverlogix Corp.

Dr. Smith holds a Doctor of Medicine degree from Dalhousie University.

### **Audit and Finance Committee Oversight**

At no time since the commencement of the Corporation's most recently completed financial year was a recommendation of the Audit and Finance Committee to nominate or compensate an external auditor not adopted by the Board.

### **Reliance on Certain Exemptions**

Since the commencement of the Corporation's most recently completed financial year, it has not relied on the exemption in section 2.4 (*De Minimus Non-audit Services*) or an exemption granted under Part 8 (*Exemptions*) of NI 52-110.

### **Pre-Approval Policies and Procedures**

The Corporation will not engage external auditors to carry out any Prohibited Service as defined in the CICA revised Rules of Professional Conduct.

The Board, upon recommendation from the Audit and Finance Committee, will consider the pre-approval of permitted services to be performed by the external auditors in each of the following broad categories:

- Audit Services
- Audit Related Services
- Tax Services

Engagements of external auditors will only commence subsequent to Board pre-approval of audit services, and only a member of the Audit and Finance Committee, or the President and CEO or Chief Financial Officer shall be authorized to request services of external auditors.

### External Auditor Service Fees

The following table sets out the aggregate fees billed by our external auditor in fiscal 2014 for services provided to the Corporation:

Financial Year Ending April 30	Audit Fees <sup>(1)</sup>	Audit Related Fees <sup>(2)</sup>	Tax Fees <sup>(3)</sup>	All Other Fees <sup>(4)</sup>
2014	\$110,000	\$Nil	\$Nil	\$Nil

**Notes:**

1. Fees paid for the audit of the annual financial statements and other regulatory audits and filings.
2. Fees paid for assurance and related services that are reasonably related to the performance of the audit or review of the Corporation's financial statements that are not disclosed in the "Audit Fees" column.
3. Fees paid for tax compliance, tax advice, tax planning and advisory services.
4. Fees paid for professional services other than those listed in the previous three columns.

### Exemption

The disclosure in this section is being provided in reliance upon the exemption in Section 6.1 of NI 52-110 because the Corporation is a venture issuer and, therefore, it is not required to file an annual information form.

## DISCLOSURE OF CORPORATE GOVERNANCE PRACTICES

### General

The Board and senior management of the Corporation consider good corporate governance to be central to the effective operation of the Corporation and are committed to maintaining a high standard of corporate governance.

The Board has delegated primary responsibility for the development of certain governance practices and mechanisms to the Corporate Governance and Nominating Committee. The Corporate Governance and Nominating Committee's charter provides that the responsibilities of such committee include: (i) establishing and reviewing member characteristics for the Board; (ii) evaluating, identifying and recommending nominees to the Board; (iii) monitoring and reviewing the education and development of members of the Board; (iv) recommending directors to serve as committee members and chairs; (v) reviewing and developing corporate governance guidelines, policies and procedures for the Board; (vi) establishing and implementing evaluation processes for the Board, committees and chairs; (vii) establishing procedures for the engagement of independent counsel by a director; (viii) reviewing disclosure by the Corporation of matters within the committee's mandate; and (ix) reviewing and evaluating the committee's charter and efficacy.

The Board and the Corporation have devoted significant attention and resources to reviewing the Corporation's corporate governance practices and ensuring that the Corporation's system of corporate governance will meet applicable legal requirements on an ongoing basis. The Board adopted its Terms of Reference ("**Terms of Reference**") and a number of policies including policies related to insider trading, disclosure and the media, and a whistleblower policy, to assist the Corporation in maintaining a high standard of corporate governance. With input from the relevant committees, the Board also created the charters for its committees: the Audit and Finance Committee, the Compensation and HR Committee, and the Corporate Governance and Nominating Committee.

The Board and the Corporation has adopted Corporate Governance Guidelines (which set out the responsibilities of the Board as a whole, the structure of the Board, the responsibilities of directors and

other matters related to the operations of the Board) and a Code of Ethics and Business Conduct (which is applicable to all directors, officers and employees of the Corporation).

In March and June 2014, the Corporate Governance and Nominating Committee conducted its annual review of the Corporation's governance policies, charters and terms of reference and minor amendments were recommended. The Board is committed to continuing to monitor new developments relating to governance best practices to ensure the Corporation is achieving compliance and implementing processes accordingly.

In July 2014, the Board of the Corporation appointed Mr. Donald J. McCaffrey as Chairman and Dr. Peter Johann as Lead Director and position descriptions have been approved for these positions. Since Mr. McCaffrey is not an independent Chairman, Dr. Johann, as Lead Director, will work to ensure that the board operates independently of management and that Board members have an independent leadership contact.

Set out below is a description of certain corporate governance practices of the Corporation.

### Board of Directors

National Policy 58-201 – *Corporate Governance Guidelines* recommends that boards of directors of reporting issuers be composed of a majority of independent directors. The Board is currently comprised of six directors, all of whom are being proposed for re-election at the Meeting. Pursuant to the Terms of Reference, the Board is responsible for assessing director independence. The Board has assessed the independence of each director in accordance with National Instrument 58-101 – *Disclosure of Corporate Governance Practices* and National Instrument 52-110 – *Audit Committees* (“**NI 52-110**”). Following this assessment as at the Effective Date, the Board concluded that four of the six existing directors (and therefore a majority of the directors), being Dr. Johann, Mr. McNeill, Dr. Smith and Mr. Zuerblis are independent. Mr. McCaffrey and Dr. Cherrington are not considered independent by virtue of their respective previous and current executive positions with the Corporation.

The Corporation and the Board recognize the significant commitment involved in being a member of the Board. The Corporate Governance Guidelines set out rules regarding limitations on the number of boards of other publicly traded companies on which a director may serve, the minimum number of Board meetings to be held annually by the Corporation, orientation and continuing education for Board members, as well as Board and management responsibilities.

Currently, the following directors serve on the boards of directors of other reporting issuers in Canada (or the equivalent in a foreign jurisdiction) as listed below. With the exception of Dr. Cherrington, all of the other directors currently serve together on the board of Resverlogix Corp., a TSX company.

Director	Public Company Board Membership
Donald J. McCaffrey	Resverlogix Corp. - TSX
Dr. Peter Johann	Resverlogix Corp. - TSX
Kelly McNeill	Resverlogix Corp. - TSX
Dr. Eldon R. Smith	Canadian Natural Resources Ltd. – TSX/NYSE Aston Hill Financial Inc. – TSX Intellipharma International Inc. – TSX/NASDAQ Resverlogix Corp. - TSX
Kenneth Zuerblis	Stemline Therapeutics, Inc. – NASDAQ Resverlogix Corp. – TSX
Dr. Julie M. Cherrington	N/A

The Board generally meets five times a year and additionally during the year as the need arises. The frequency and length of meetings and the nature of agenda items depend upon the circumstances. Meetings are generally lengthy, detailed and well attended, and are conducted in an atmosphere that encourages participation and independence. In order to promote candid discussion among the independent

directors, an in-camera session is considered at every board and committee meeting, from which Mr. McCaffrey (as was the case for the most recently completed fiscal year), Dr. Cherrington (for the upcoming fiscal year), and any management invitees in attendance are recused.

### **Orientation and Continuing Education**

Each new director on the Board is provided with a director's manual, which is updated on a regular basis. New members are expected to review and become familiar with its contents. The director's manual contains the Board Terms of Reference, committee terms of reference, Corporate Governance Guidelines, the Code of Business Conduct and Ethics and the position descriptions of any officers and Committee Chairs, other key corporate policies and relevant corporate and Board information.

The Corporation also provides directors with opportunities to increase their knowledge and understanding of the Corporation's business. Briefings on strategic issues are conducted regularly, and typically include reviews of the competitive environment, the Corporation's performance relative to its peers, and any other developments that could materially affect the Corporation's business. In addition, the Board is briefed on a regular basis on corporate governance developments and emerging best practices in corporate governance.

### **Ethical Business Conduct**

The Board adopted a Code of Business Conduct and Ethics ("**Code**") which sets out in detail the purpose, scope and application of the Code and outlines general principles by which the Corporation is governed. The Code and the method of administering the Code, handling inquiries and complaints, investigating violations, and reporting to the Board on matters related to the Code has been communicated to directors, officers and employees. The Code is available on the Corporation's website and has been filed on and is accessible through SEDAR at [www.sedar.com](http://www.sedar.com).

The Board and the Audit and Finance Committee has also established a Whistleblower Policy and engaged an independent whistleblower service provider to encourage employees, officers and directors to raise concerns regarding any matters, including accounting, internal controls or auditing matters, on a confidential basis free from discrimination, retaliation or harassment. A report on the status of any matters arising from the Whistleblower Policy is provided at each meeting of the Audit and Finance Committee.

In addition, in order to ensure independent judgment in considering transactions/agreements in which a director/officer has a material interest, all related party transactions are approved by the independent directors and all payments under related party transactions are approved by the Audit and Finance Committee.

### **Nomination of Directors**

The responsibility for identifying new candidates for Board nomination has been delegated to the Corporate Governance and Nominating Committee. As of the Effective Date, the Corporate Governance and Nominating Committee is comprised of Dr. Smith (as Chair), Dr. Johann and Mr. McNeill, all of whom are independent directors. For further information concerning the responsibilities, powers and operations of the Corporate Governance and Nominating Committee see above under "General". If a vacancy occurs on the Board, or if additional members are deemed necessary, the Corporate Governance and Nominating Committee will, in consultation with the President and CEO, identify candidates who satisfy the skills and characteristics criteria and the long-term plan for the Board composition established by such committee. The Corporate Governance and Nominating Committee will recommend such candidates to the Board for appointment.

### **Compensation**

Further information regarding the activities of the Compensation and HR Committee is provided under the heading "Executive Compensation" elsewhere in this Management Information Circular.

### **Other Board Committees**

The Board does not have any standing committees other than the Audit and Finance Committee, the Corporate Governance and Nominating Committee and the Compensation and HR Committee.

The Board from time to time and on an ad hoc basis may determine it to be in the best interests of the Corporation to form special committees of the Board to review or investigate specific matters and report findings or recommendations to the Board for further consideration. Following the completion or finalization of the matter or purpose for which the special committee had been established, the special committee is dissolved and ceases to exist.

### **Board Assessments**

In June 2014, the Corporate Governance and Nominating Committee coordinated, and the Board completed its annual formal evaluation process to assess the effectiveness of the Board as a whole, including a general review of the committees of the Board and the contribution of individual directors. The results of the evaluation and recommendations relating thereto were discussed and considered by the Board and action items were addressed accordingly.

### **INTEREST OF INFORMED PERSONS OR COMPANIES IN MATTERS TO BE ACTED UPON**

To the knowledge of the Board and management of the Corporation, no director or executive officer of the Corporation or anyone who has held office as such since the beginning of the last financial year of the Corporation nor any proposed nominee for election as a director of the Corporation or of any associate or affiliate of any of the foregoing has a material interest, direct or indirect, by way of beneficial ownership of securities or otherwise, in any matter to be acted on at the Meeting, except as otherwise disclosed herein.

### **INTEREST OF CERTAIN PERSONS IN MATERIAL TRANSACTIONS**

Other than as set forth below, to the knowledge of the Board and management of the Corporation, none of the Corporation's directors, executive officers or companies or persons that beneficially own or control or direct, directly or indirectly, or a combination of both, more than 10 percent of the Corporation's Common Shares, proposed nominees for election as directors of the Corporation or any of their respective associates or affiliates, has any material interest in any transaction with the Corporation since the commencement of the Corporation's last financial year, or in any proposed transaction which has materially affected or would materially affect the Corporation or any of its subsidiaries.

In March 2014, the Corporation closed a private placement of 8,000,000 Common Shares at a price of US\$1.00 per share for gross proceeds of US\$8,000,000 (the "Private Placement") to Eastern Capital Limited ("Eastern") and NGN BioMed Opportunity II, L.P. ("NGN"). Eastern and NGN subscribed for 6,000,000 and 2,000,000 Common Shares, respectively. The Common Shares are subject to a four month hold period.

Pursuant to the terms of the Private Placement, in the event that Zenith completes an equity financing within 18 months and the price per share is lower than US\$1.00, the price per share paid by Eastern and NGN will be adjusted to the lower price per share and they will, accordingly, receive additional common shares for no additional consideration. Furthermore, in the event that Zenith completes an equity financing within 18 months and Zenith issues or grants additional securities, contractual rights or entitlements to any of the subscribers, then Zenith shall issue or grant the same additional securities, contractual rights or entitlements to Eastern and NGN. Additionally, in the event that Zenith receives gross proceeds from equity financings of less than US\$25 million and grants a license to a third party, sells intellectual property rights to a third party, or greater than 662/3% of Zenith's common shares are sold to a third party, NGN and Eastern shall receive, for no additional consideration, additional common shares equal to the number originally subscribed for by each party as described above.

In connection with the closing of the Private Placement, the Corporation also agreed to provide Eastern with certain "demand" and "piggy back" registration rights should it wish to sell their Common Shares by way of a prospectus.

In July 2014, the Corporation closed a further private placement of 4.3 million Common Shares at a price of US\$1.00 per share for gross proceeds of CAD\$4.6 million. NGN subscribed for 1,000,000 Common Shares, which are subject to a four month hold period. Pursuant to the terms of the private placement, in the event that the Corporation completes an equity financing within 18 months and the price per share is lower than US\$1.00, the price per share paid by NGN will be adjusted to the lower price per share and NGN will, accordingly, receive additional common shares for no additional consideration.

#### **INDEBTEDNESS OF DIRECTORS AND EXECUTIVE OFFICERS**

No director, proposed director, officer, nor any of their respective associates is or has been at any time during the financial year ended April 30, 2014 been indebted to the Corporation or any of its subsidiaries, nor has any such individual been indebted to any other entity where such indebtedness is the subject of a guarantee, support agreement, letter of credit or similar arrangement or understanding provided by the Corporation or any of its subsidiaries.

#### **OTHER MATTERS**

As of the date of this Management Information Circular, the Board and management know of no amendment, variation or other matter to come before the Meeting other than the matters referred to in the Notice of Meeting; however, if any other matter properly comes before the Meeting, proxies in favour of management nominees will be voted on such matter in accordance with the best judgment of the person or persons voting the proxy.

The contents and the sending of this Management Information Circular have been approved by the Directors of the Corporation.

#### **ADDITIONAL INFORMATION**

Additional information relating to the Corporation is available on SEDAR at [www.sedar.com](http://www.sedar.com). Financial information relating to the Corporation's most recently completed financial year is provided in the Corporation's comparative financial statements and management's discussion and analysis available on SEDAR. A shareholder may contact the Corporation at 300, 4820 Richard Road SW, Calgary, Alberta, T3E 6L1, Attention: CFO, to obtain a copy of the Corporation's most recent financial statements and management discussion and analysis.

Dated August 25, 2014

**APPENDIX A**

**ZENITH EPIGENETICS CORP.  
AUDIT AND FINANCE COMMITTEE - CHARTER**

# ZENITH EPIGENETICS CORP. AUDIT & FINANCE COMMITTEE CHARTER

## PART I ESTABLISHMENT OF COMMITTEE

### 1. Committee Purpose

The Audit and Finance Committee (the "**Committee**") is established by the board of directors (the "**Board of Directors** ") of Zenith Epigenetics Corp. (the "**Corporation**") primarily for the purpose of overseeing the accounting and financial reporting processes of the Corporation and the reviews and audits of the financial statements of the Corporation.

The Committee shall assist the Board of Directors in fulfilling its oversight responsibilities by monitoring, among other things:

- (a) the quality and integrity of the financial statements and related disclosure of the Corporation;
- (b) compliance by the Corporation with legal and regulatory requirements that could have a material effect upon the financial position of the Corporation which are not subject to the oversight of another committee of the Board of Directors or the Board of Directors as a whole;
- (c) the independent auditor's qualifications and independence; and
- (d) performance of the Corporation's independent auditor.

### 2. Composition of Committee

The Committee shall consist of as many members as the Board shall determine, but in any event not fewer than three directors, provided that all of the members of the Committee shall be determined by the Board to be independent within the meaning of National Instrument 52-110 (Audit Committees), Rule 10A-3(b)(1) under the United States Securities Exchange Act of 1934 and the rules of any stock exchange or market on which the Corporation's shares are listed or posted for trading, if any (collectively, "**Applicable Governance Rules**"). In this Charter, the term "independent" includes the meanings given to similar terms by Applicable Governance Rules, including the terms "non-executive", "outside" and "unrelated" to the extent such terms are applicable under Applicable Governance Rules. No member of the Audit Committee shall have participated in the preparation of the financial statements of the Corporation or any current subsidiary of the Corporation at any time during the past three (3) years.

All members of the Audit Committee must be able to read and understand fundamental financial statements (including a balance sheet, income statement and cash flow statement) and read and understand a set of financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and level of complexity of the issues that can reasonably be expected to be raised by the Corporation's financial statements. In addition: (i) at least one member of the Audit Committee must have past employment experience in finance or accounting, requisite professional certification in accounting or any other comparable experience or background that results in the individual's financial sophistication, including service as a chief executive officer, chief financial officer, or other senior officer with financial oversight responsibilities or otherwise satisfy standards for financial expertise required for audit committees of companies listed on the NASDAQ Stock Market, and (ii) at least one member of the Audit Committee must be an "audit committee financial expert" as defined by the applicable rules set out by the United States Securities and Exchange Commission or any other applicable regulatory authority.

### **3. Appointment of Committee Members**

The members of the Committee shall be appointed by the Board of Directors on the recommendation of the Corporate Governance and HR Committee. The members of the Committee shall be appointed at the time of each annual meeting of shareholders and shall hold office until the next annual meeting, until they are removed by the Board of Directors or until their successors are earlier appointed, or until they cease to be directors of the Corporation.

## **PART II COMMITTEE PROCEDURE**

### **4. Vacancies**

Where a vacancy occurs at any time in the membership of the Committee, it may be filled by the Board of Directors on the recommendation of the Corporate Governance and HR Committee and shall be filled by the Board of Directors if the membership of the Committee is fewer than three directors. The Board of Directors may remove and replace any member of the Committee.

### **5. Committee Chair**

The Board of Directors shall appoint a chair (the "**Chair**") for the Committee. The Chair may be removed and replaced by the Board of Directors.

### **6. Absence of Chair**

If the Chair is not present at any meeting of the Committee, one of the other members of the Committee present at the meeting shall be chosen by the Committee to preside at the meeting.

### **7. Secretary of Committee**

The Committee shall appoint a Secretary who need not be a director of the Corporation.

### **8. Regular Meetings**

The Chair, in consultation with the Committee members, shall determine the schedule and frequency of the Committee meetings, provided that the Committee shall meet at least quarterly. The Committee at any time may, and at each regularly scheduled Committee meeting shall, meet without management present and shall meet periodically with management and the independent auditor. The Committee shall also meet separately with the independent auditor at every regularly scheduled meeting of the Committee at which the independent auditor is present. The Committee shall record and maintain minutes of meetings.

### **9. Special Meetings**

The Chair, any two members of the Committee, the independent auditor or the Chief Executive Officer of the Corporation may call a special meeting of the Committee.

### **10. Quorum**

A majority of the members of the Committee, present in person or by telephone or other telecommunication device that permits all persons participating in the meeting to speak to each other, shall constitute a quorum.

#### **11. Notice of Meetings**

Notice of the time and place of every meeting shall be given in writing or by e-mail or facsimile communication to each member of the Committee at least 48 hours prior to the time fixed for such meeting; provided, however, that a member may, in any manner, waive notice of a meeting and attendance of a member at a meeting is a waiver of notice of the meeting, except where a member attends a meeting for the express purpose of objecting to the transaction of any business on the grounds that the meeting is not lawfully called.

#### **12. Agenda**

The Chair shall develop and set the Committee's agenda, in consultation with other members of the Committee, the Board of Directors and management of the Corporation. The agenda and information concerning the business to be conducted at each Committee meeting shall, to the extent practicable, be communicated to the members of the Committee sufficiently in advance of each meeting to permit meaningful review.

#### **13. Delegation**

Subject to subsection PART III19(e), the Committee shall have the power to delegate its authority and duties to subcommittees or individual members of the Committee as it deems appropriate.

#### **14. Access**

In discharging its oversight role, the Committee shall have full access to all books, records, facilities and personnel of the Corporation.

#### **15. Attendance of Others at a Meeting**

At the invitation of the Chair, one or more officers, directors or employees of the Corporation may, and if required by the Committee shall, attend a meeting of the Committee.

#### **16. Procedure, Records and Reporting**

The Committee shall fix its own procedure at meetings, keep records of its proceedings and report to the Board of Directors when the Committee may deem appropriate (but not later than the next meeting of the Board of Directors).

#### **17. Outside Consultants or Advisors**

The Committee, when it considers it necessary or advisable, may retain, at the Corporation's expense, outside consultants or advisors (including independent counsel) to assist or advise the Committee independently on any matter within its mandate. The Committee shall have the sole authority to retain or terminate such consultants or advisors, including the sole authority to approve the fees and other retention terms for such persons.

### **PART III MANDATE OF COMMITTEE**

#### **18. Appointment of the Corporation's Independent Auditor**

Subject to confirmation by the independent auditor of its compliance with Canadian regulatory registration requirements, the Committee shall recommend to the Board of Directors the appointment of the independent auditor for the purpose of preparing or issuing any audit report or performing other audit,

review or attest services for the Corporation, such appointment to be confirmed by the Corporation's shareholders at each annual meeting. The Committee shall also recommend to the Board of Directors the engagement letter with the independent auditor, the approval of fees to be paid to the independent auditor for audit services and shall pre-approve the retention of the independent auditor for any permitted non-audit service. The Committee shall also be directly responsible for overseeing the work of the independent auditor (including resolution of disagreements between management of the Corporation and the independent auditor regarding financial reporting) for the purpose of preparing or issuing an audit report or performing other audit, review or attest services for the Corporation. The Committee shall communicate directly with the independent auditor. The independent auditor shall report directly to the Committee.

The Committee shall review the independence of the independent auditor including a written report from the independent auditor delineating all relationships between the auditor and the Corporation, considering whether the advisory services performed by the independent auditor during the course of the year have affected its independence, and ensuring that no relationship or service between the independent auditor and the Corporation is in existence that may affect the objectivity and independence of the auditor, or recommending appropriate action to ensure the independence of the independent auditor.

## **19. Specific Mandates**

The Committee, to the extent required by applicable laws or rules, or otherwise considered by the Committee to be necessary or appropriate, shall:

### **(a) Oversight in Respect of Financial Disclosure**

- (i) review, discuss with management of the Corporation and the independent auditor, and recommend to the Board of Directors for approval:
  - A. the annual and interim financial statements;
  - B. the annual information form, if any;
  - C. the annual and interim management's discussion and analysis;
  - D. the portions of the management proxy circular, for any annual or special meeting of shareholders, containing significant financial information respecting the Corporation;
  - E. all financial statements included in prospectuses or other offering documents;
  - F. any significant financial information contained in all prospectuses and all documents which may be incorporated by reference in a prospectus;
  - G. any significant financial information respecting the Corporation contained in a material change report or a business acquisition report;
- (ii) review and discuss with management of the Corporation:
  - A. each press release which contains significant financial information respecting the Corporation (including, without limitation, annual and interim earnings press releases) or contains earnings guidance, prior to public dissemination thereof;

- B. the use of "pro forma" or "adjusted" non-IFRS information;
  - C. financial information and earnings guidance provided to analysts and rating agencies; provided, however, that such discussion may be done generally (consisting of discussing the types of information to be disclosed and the types of presentations to be made), and the Committee need not discuss in advance each instance in which the Corporation may provide earnings guidance or presentations to rating agencies;
- (iii) review with management and the independent auditor the scope of the audit, in particular the independent auditor's view of the Corporation's accounting principles as applied in the financial statements in terms of disclosure quality and evaluation methods, inclusive of the clarity of the Corporation's financial disclosure and reporting, degree of conservatism or aggressiveness of the Corporation's accounting principles and underlying estimates, and other significant decisions made by management in preparing the financial disclosure and reviewed by the independent auditor;
  - (iv) review with management of the Corporation and the independent auditor major issues regarding accounting and auditing principles and practices as well as the adequacy of internal controls and procedures for financial reporting and management information systems and inquire of management and the independent auditor about significant risks and exposures to the Corporation that could significantly affect the Corporation's financial statements;
  - (v) review with management of the Corporation and the independent auditor, and satisfy itself as to the adequacy of the procedures that are in place for the review of the Corporation's disclosure of financial information extracted or derived from the Corporation's financial statements, and periodically assess the adequacy of those procedures;
  - (vi) review with management of the Corporation and the independent auditor (including those of the following that are contained in any report of the independent auditor): (a) all critical accounting policies and practices to be used by the Corporation in preparing its financial statements; (b) all alternative treatments of financial information within IFRS that have been discussed with management, ramifications of the use of these alternative treatments, and the independent auditor's assessment of the alternatives; and (c) other material communications between the independent auditor and management of the Corporation, such as any management letter or schedule of unadjusted differences;
  - (vii) review with management of the Corporation and the independent auditor the effect of regulatory and accounting initiatives as well as off-balance sheet transactions on the Corporation's financial statements;
  - (viii) review the plans of management of the Corporation and the independent auditor regarding any significant changes in accounting practices or policies and the financial and accounting impact thereof;
  - (ix) review with management of the Corporation, the independent auditor and, if necessary, legal counsel, any litigation, claim or contingency, including tax assessments, that could have a material effect upon the financial position of the

Corporation, and the manner in which these matters have been disclosed in the financial statements;

- (x) review disclosures by the Corporation's Chief Executive Officer and Chief Financial Officer with respect to any required certification for the Corporation's financial statements by such individuals; and
- (xi) discuss with management the Corporation's material financial risk exposures and the steps management of the Corporation has taken to monitor and control such exposures, including the Corporation's financial risk assessment and financial risk management policies.

**(b) Oversight in Respect of Legal and Regulatory Matters**

- (i) review, if necessary, with legal counsel, the Corporation's compliance policies, legal matters and any material reports or inquiries received from regulators or governmental agencies that could have a material effect upon the financial position of the Corporation and which are not subject to the oversight of another committee of the Board of Directors or the Board of Directors as a whole.

**(c) Oversight in Respect of the Chief Financial Officer**

- (i) consult with management on management's appointment, replacement, reassignment or dismissal of the Chief Financial Officer of the Corporation; and
- (ii) ensure the Chief Financial Officer of the Corporation has access to the Chair, the Chairman of the Board of Directors and the Chief Executive Officer of the Corporation, and shall meet separately with the Chief Financial Officer of the Corporation to review any problems or difficulties he or she may have encountered in the performance of his or her responsibilities and report to the Board of Directors on such meetings.

**(d) Oversight in Respect of the Independent Auditor**

- (i) meet with the independent auditor prior to the annual audit to review the planning and staffing of the audit;
- (ii) review annually the independent auditor's formal written statement of independence delineating all relationships between itself and the Corporation and review all such relationships;
- (iii) receive confirmation from the independent auditor as to its standing as a "participating audit firm" and its compliance with any restrictions or sanctions imposed by the Canadian Public Accountability Board as those concepts are set forth in National Instrument 52-108 of the Canadian Securities Administrators;
- (iv) review and evaluate the independent auditor, including the lead partner of the independent auditor team and shall confirm compliance by the independent auditors with laws and regulations relating to audit partner rotation;
- (v) meet separately with the independent auditor to review with them any problems or difficulties they may have encountered and specifically:

A. any difficulties which were encountered in the course of the audit work, including any restrictions on the scope of activities or access to required information, and any disagreements with management of the Corporation; and

B. any changes required in the planned scope of the audit;

and report to the Board of Directors on such meetings;

(vi) review the engagement reports of the independent auditor on unaudited financial statements of the Corporation; and

(vii) review and approve the Corporation's hiring policies regarding partners, employees, former partners and former employees of the Corporation's present and former independent auditor.

(e) **Oversight in Respect of Audit and Non-Audit Services**

(i) have the sole authority to pre-approve all audit services (which may entail providing comfort letters in connection with securities underwritings) and all permitted non-audit services, other than non-audit services where:

A. the aggregate amount of all such non-audit services provided to the Corporation or its subsidiaries constitutes not more than 5% of the total amount of fees paid by the Corporation (and its subsidiaries) to the independent auditor during the fiscal year in which the non-audit services are provided;

B. such services were not recognized by the Corporation (or any subsidiary) at the time of the engagement to be non-audit services; and

C. such services are promptly brought to the attention of the Committee and approved, prior to the completion of the audit, by the Committee or by one or more members of the Committee to whom authority to grant such approvals has been delegated by the Committee; and

(ii) delegate to one or more designated members of the Committee the authority to grant pre-approvals required by this section; provided that the decision of any member to whom authority is delegated to pre-approve an activity shall be presented to the Committee at the first scheduled meeting following such decision, and provided further that, if the Committee approves an audit service within the scope of the engagement of the independent auditor, such audit service shall be deemed to have been pre-approved for purposes of this section

(f) **Oversight in Respect of Certain Policies**

(i) establish procedures for: (a) the receipt, retention and treatment of complaints received by the Corporation regarding accounting, internal accounting controls or auditing matters; and (b) the confidential, anonymous submission by employees of the Corporation of concerns regarding questionable accounting or auditing matters; and

(ii) periodically review the Corporation's public disclosure policy.

**20. Evaluation of Code of Business Conduct and Ethics**

The Committee shall conduct an annual assessment of management's adherence to the Corporation's Code of Business Conduct and Ethics.

**21. Non-Exhaustive List**

The foregoing list of duties is not exhaustive, and the Committee may, in addition, perform such other functions as may be necessary or appropriate for the performance of its oversight responsibilities.

**22. Review of Committee's Charter**

The Committee shall assess the adequacy of this Charter on an annual basis and recommend any changes to the Board of Directors.

**23. Oversight Function**

While the Committee has the responsibilities and powers set forth in this Charter, it is not the duty of the Committee to plan or conduct audits or to determine that the Corporation's financial statements are complete and accurate or are in accordance with IFRS. These are the responsibilities of management of the Corporation and the independent auditor. The Committee and its Chair are members of the Board of Directors, appointed to the Committee to provide broad oversight of the financial risk and control related activities of the Corporation, and are specifically not accountable nor responsible for the day to day operation or performance of such activities. The role of all Committee members is to oversee the process, not to certify or guarantee the accuracy or completeness of the external audit of the Corporation's financial information or public disclosure.



